Braxia Scientific Low on Cash and Looking for a Deal

The company is reviewing strategic alternatives including selling the company.

Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) reported its earnings for the fiscal second quarter of 2024 ended Sept. 30, with revenue up 30.5% to $594,000 from the same period a year ago.

Net loss for Braxia Scientific was $275,000 for the quarter versus last year’s net loss of $2.16 million.

As of Sept. 30, company’s cash and cash equivalents were $701,000 with a working capital deficit of $961,000.

Challenging Environment

Despite the improvements in revenue, Braxia has essentially come to the end of its runway and is looking for strategic alternatives. The company said that the process will begin immediately and that it will evaluate a broad range of options, including:

  • Potential sale of the company.
  • Merger or other business combination.
  • Sale of all or a portion of the company’s assets.
  • Strategic investment or other significant transaction.

Braxia also told investors that it has received strategic inquiries from multiple parties over the past few months.

“Looking ahead, the board has formally initiated a process to explore strategic alternatives and alternative sources of capital or partnerships that may be available to the company following continued challenges in the economic environment and in accessing capital through public markets,” CEO Dr. Roger McIntyre said. “While I remain confident in the continued growth of our clinics, if we are unable to raise additional funding in the short term, we will look at alternate courses of actions including, but not limited to, further cost reductions, restructuring, and the potential scaling back of clinic locations.”

The company has not set a timetable for implementing a plan and won’t update investors again unless it signs a deal. Braxia also warned investors that even if it attempts to make a deal, there are no assurances that one will be struck.


In addition to the dire financial situation, Braxia has seen a number of key team members jumpship.

Olga Cwiek, a member of the board of directors, resigned this week, as did CFO Stephen Brooks.

Peter Rizakos, chief legal officer, was appointed to the board and will also take on the role of chief financial officer.

Even though the company is struggling financially, the clinics have been slowly growing.

“Our clinics experienced higher treatment volumes in the first half of fiscal 2024 resulting in strong revenue growth,” McIntyre said. “This demonstrates the demand for critical mental health treatments and therapies that our team of specialized psychiatrists, doctors and nurses provide across our clinical footprint.”

He added: “Our team has continued to focus on reducing expenses and improving efficiencies while also looking to add novel therapies and other support services to our clinical platform to further improve revenues.”

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.